Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 8/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
| ▸ | SELE | P16581 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10949281 | 0.81 | MAPK1 (0.45) | GPR35ESR1ICAM1SELECES2 | |
| SCHEMBL5244202 | 0.78 | ESR1 (0.48) | ESR1 | |
| SCHEMBL5196415 | 0.72 | ESR1 (0.43) | ESR1GAA | |
| SCHEMBL5242224 | 0.72 | ESR1 (0.47) | ESR1 | |
| SCHEMBL14566790 | 0.71 | ESR1 (0.41) | ESR1 | |
| SCHEMBL29121145 | 0.70 | HDAC3 (0.45) | NPC1RAB9ALMNAGAAMAPT | |
| SCHEMBL9757077 | 0.69 | GPR35 (0.65) | GPR35ICAM1SELEBCL2L1MCL1 | |
| SCHEMBL9756981 | 0.69 | MAPK1 (0.53) | GPR35ICAM1SELELMNAGAA | |
| SCHEMBL121901 | 0.68 | MCL1 (0.57) | GPR35NPC1RAB9AF10LMNA | |
| SCHEMBL8637183 | 0.67 | ESR1 (0.60) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022125-A1 | PYRROLOPYRIDAZINE VEGFR INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022125-A1 | PYRROLOPYRIDAZINE VEGFR INHIBITORS | FLT1, KDR, FLT4 | GPR35 725/4885ESR1 795/4885NPC1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.